14 February 2025

Insights from Advanced Therapies Week 2025

Evolving Landscape of Cell and Gene Therapy (CGT) Manufacturing: Key Takeaways from Natalia Elizalde.

Read more

11 February 2025

Celebrating women in science: honoring talent and innovation at VIVEbiotech

On the International Day of Women and Girls in Science, we recognize the invaluable contributions of women in advancing science.

Read more

4 February 2025

VIVEbiotech joins the fight on World Cancer Day

Supporting Patients, Families, and Groundbreaking Therapies in the Battle Against Cancer.

Read more

23 January 2025

VIVEbiotech wins the CMO/CDMO of the Year Award at the Advanced Therapies Awards

We are overjoyed to announce that VIVEbiotech has been named the “CMO/CDMO of the Year” at the prestigious Advanced Therapies Awards, held last night...

Read more

21 January 2025

VIVEbiotech Shines at Advanced Therapies Week in Dallas

This week, VIVEbiotech proudly participates in the Advanced Therapies Week hosted by Phacilitate at the Kay Bailey Hutchison Convention Center, Dallas.

Read more

15 January 2025

VIVEbiotech named finalist for CMO/CDMO of the Year at Advanced Therapies Awards

Excitement builds as our team heads to Dallas for Advanced Therapies Week conference.

Read more

8 January 2025

VIVEbiotech’s Expertise Highlighted in Drug Discovery World’s 2025 Predictions

Natalia Elizalde shares insights on the future of cell and gene therapy.

Read more

20 December 2024

Merry Christmas and Happy New Year from our extraordinary team

As the year winds down, we’re filled with gratitude for the incredible journey that was 2024 for VIVEbiotech.

Read more

16 December 2024

VIVEbiotech will be exhibiting at the Advanced Therapies Week in Dallas

VIVEbiotech will be an exhibitor at Phacilitate's Advanced Therapies Week to be held in Dallas from January 20-23.

Read more

4 December 2024

VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity...

Read more